InnoCare Reports Response Rate in Phase II Lymphoma Study
InnoCare said its orelabrutinib combination achieved a response rate in a Phase II study of marginal zone lymphoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.